WVSHP Logo Contact Information
News & Events

News from WVSHP

2019 Spring Meeting - Save the date SAVE THE DATE for the Spring Meeting 2019 April 26th and 27th, 2019 Embassy Suites, Charleston, WV (Click for more...)

News from elsewhere...
Put your agency in the spotlight, ENTER NOW 7/13/2018 8:05:55 AM “The ‘NHS Challenge’ is designed specifically for agencies that have strong experience in dealing with UK specific challenges,” says the executive steering group's Eric Hansen. (Click for more...) Recognising the outstanding achievements of medical and scientific professionals 7/13/2018 7:56:34 AM PharmaTimes Media has announced the Medical & Scientific Excellence Awards as the latest addition to its highly prestigious portfolio of events - and now is the time to enter! (Click for more...) Brexit ambition is ‘fine’ but execution is key, says Brexit Health Alliance 7/13/2018 5:46:29 AM "There is always a danger that health issues are not kept to the fore" in negotiations, says Niall Dickson (Click for more...) NICE turns down Darzalex combo for pre-treated multiple myeloma 7/12/2018 6:40:03 PM Janssen says it is disappointed that NHS cost regulators are not backing NHS use of Darzalez (daratumumab) plus bortezomib and dexamethasone (DBd) for previously treated multiple myeloma in adults. (Click for more...) GSK sells psoriasis/dermatitis therapy to Dermavant 7/12/2018 6:36:10 PM GlaxoSmithKline has sold rights to an experimental therapy being developed for psoriasis and dermatitis to Dermavant in a deal worth $330 million. (Click for more...) Zogenix’ drug cuts seizures in Dravet syndrome 7/12/2018 6:32:07 PM Zogenix has revealed top-line results from a second late-stage trial of its investigational Dravet syndrome drug ZX008, showing a significant reduction in seizures. (Click for more...) NHS under ‘intolerable’ strain 7/12/2018 6:28:51 PM NHS Confederation chief executive Niall Dickson is warning that the NHS is “under intolerable strain”, after the latest performance data continue to show growing demand and missed targets. (Click for more...) Roche’s Venclexta filed in the US for acute myeloid leukemia 7/12/2018 5:32:42 AM Roche group Genentech has filed an application to market Venclexta in the US for acute myeloid leukemia (AML). (Click for more...) NICE backs Qarziba for children with high-risk neuroblastoma 7/12/2018 5:07:10 AM NHS funding for EUSA’s Pharma’s Qarziba has been approved to treat children with high-risk neuroblastoma. (Click for more...) AbbVie, J&J’s Imbruvica fails to target in B-Cell lymphoma trial 7/12/2018 5:00:27 AM AbbVie and Johnson & Johnson’s Imbruvica has failed to meet its key target in a late stage study assessing its use in patients with treatment-naïve diffuse large B-cell lymphoma. (Click for more...) Pfizer re-organises into three business units 7/12/2018 4:55:02 AM Pfizer has announced a re-organisation of its operations into three distinct businesses. (Click for more...) NICE backs use of dye for brain tumour removal 7/11/2018 6:00:39 AM NICE has published new guidelines recommending use of a chemical dye to assist neurosurgeons in removing brain tumours. (Click for more...) NHS England appoints national clinical advisor for primary care 7/11/2018 5:38:02 AM NHS England has appointed a specialist GP to encourage the spread of innovations that integrate health and social care throughout England. (Click for more...) Janssen launches PhII/III programme testing Tremfya in Crohn’s 7/11/2018 5:21:10 AM Janssen has kicked off a Phase II/III programme assessing Tremfya in Crohn's Disease. (Click for more...) Gov’t launches £10 antimicrobial research competition 7/11/2018 4:59:54 AM The government has launched a £10 million research competition to encourage the development of novel approaches to combating antimicrobial resistance and improving infection prevention and control. (Click for more...) Vitamins and mineral supplements have little benefit on CV outcomes 7/9/2018 10:41:39 AM Key Point:No significant benefits were observed with use of multivitamins, vitamin D, calcium, or vitamin C on cardiovascular (CV) outcomes or all-cause mortality. Only low- to moderate-quality evidence supports use of folic acid to reduce CV disease and folic acid and B vitamins to reduce the risk of stroke, according to results of systematic reviews and meta-analyses published in the Journal of the American College of Cardiology. (Click for more...) Communication strategies to improve HPV vaccination rates 7/9/2018 9:55:13 AM Key Point:Providers with a persistent communication style that focuses on the benefits of HPV vaccine and a strong recommendation to accept vaccination resulted in much higher same-day vaccination rates compared with acquiescence and agreement to defer the vaccination, according to a study published in Pediatrics. (Click for more...) Corticosteroids for severe alcoholic hepatitis improves short-term outcomes 7/2/2018 9:50:40 AM Key Point:According to a study published in Gastroenterology, use of corticosteroids in patients with severe alcoholic hepatitis significantly reduced the risk of death within 28 days when compared with controls or pentoxifylline. However, no difference was seen in 6-month mortality for any treatment or controls. (Click for more...) Self-monitoring results in better BP control than clinic-based monitoring 7/2/2018 9:46:34 AM Key Point:Results of a large, 12-month, open-label, multicenter trial in patients with uncontrolled hypertension showed that self-monitoring (SM) of blood pressure (BP) with or without telemonitoring (TM) resulted in better BP control compared with clinic-based BP monitoring. Primary care clinicians were better able to titrate antihypertensive medications to meet recommended goals. (Click for more...) Emollient bath additives not effective for childhood eczema 6/26/2018 10:49:12 AM Key Point:Regular use of emollient bath additives for children aged 1 to 11 years who have atopic dermatitis/eczema, along with standard eczema management (e.g., leave-on emollients), did not result in any additional clinical benefits compared with standard management alone, according to results of an open-label trial published in BMJ. (Click for more...) Propranolol use in patients with posttraumatic stress disorder 6/26/2018 10:08:03 AM Key Point:Administration of propranolol 90 minutes before reactivation of traumatic memories resulted in significant reductions in posttraumatic stress disorder (PTSD) symptoms compared with placebo, according to results of a small study published in the American Journal of Psychiatry. (Click for more...) Updated guideline released on use of disease-modifying therapies for patients with MS 6/19/2018 10:55:54 AM Key Point:In April 2018, the American Academy of Neurology (AAN) published an updated guideline in Neurology on the use of disease-modifying agents for patients with multiple sclerosis (MS). The guideline focuses on who should start these therapies, which agents to initiate, switching between medications, and when to stop treatment. (Click for more...) Select antidiabetic medications associated with better mortality outcomes in patients with type 2 diabetes 6/19/2018 10:15:09 AM Key Point:Use of sodium–glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists were both associated with significantly lower all-cause mortality and cardiovascular (CV) mortality compared with dipeptidyl peptidase 4 (DPP-4) inhibitors and placebo/no treatment in patients with type 2 diabetes, according to results of a systematic review and network meta-analysis published in JAMA. (Click for more...) Costs of anticancer drugs have risen substantially, while clinical benefits remain similar 6/11/2018 11:03:56 AM Key Point:An observational analysis assessing trends in costs of anticancer drugs over a 10-year period compared with clinical benefits in the Journal of Oncology Practice found that monthly prices of these medications increased by a mean of 9% annually, and incremental drug costs increased by 21% annually. The magnitude of clinical benefits of these agents did not experience a similar proportional positive change. (Click for more...) Can use of menthol-containing cough drops worsen a cough? 6/11/2018 10:50:00 AM Key Point:Results of an observational study published in the Journal of the American Board of Family Medicine showed that use of cough drops was associated with a longer duration of cough compared with nonuse. A significant association was seen between cough severity and the average menthol dose per cough drop, the number of cough drops consumed per day, and the total amount of menthol consumed per day. (Click for more...)
Copyright© 2018 West Virginia Society of Health System Pharmacists. All rights reserved.